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Introduction
Bevacizumab is an approved anti-angiogenesis treatment widely used in combination with chemotherapy for patients with metastatic colorectal cancer. Whilst being an effective treatment, not all patients derive benefit, with modest survival benefits reported in unselected patient populations [1] [2] [3] . Biomarkers that may predict patient outcomes to bevacizumab are urgently needed to guide its use in patients who are most likely to benefit.
Unsupervised clustering analyses of gene expression profiles of colorectal cancer (CRC) have identified a number of molecular subtypes of the disease. Integration of these subtypes by an international panel of expert investigators in the field (Colorectal Cancer Subtyping Consortium) established four robust transcriptome-based subtypes known as consensus molecular subtypes (CMS) of CRC [4] . In order for CMS to be a useful tool for guiding patient management, studies are required to demonstrate the association of this molecular classification with treatment and survival outcomes. In this exploratory study, we applied the CMS classification to patient tumours from the MAX clinical trial in order to examine the role of CMS as a prognostic and predictive variable for bevacizumab benefit in metastatic CRC. MAX was a phase III, randomized controlled trial, conducted by the Australian Gastrointestinal Trials Group (AGITG), which met its primary end point of improved progression-free survival (PFS) for the addition of bevacizumab to capecitabinebased chemotherapy [3] . The availability of a control arm without bevacizumab treatment makes this an ideal dataset for examining predictive factors for bevacizumab. In addition, we examined the associations of CMS with other molecular and clinical features used to classify CRC including microsatellite instability (MSI), RAS mutations, BRAF mutations, CpG island methylator phenotype (CIMP) and primary tumour location (left versus right).
Methods
The MAX clinical trial Methods and design for the MAX clinical trial have been previously reported [3] . In brief, patients with unresectable metastatic CRC were randomly assigned to first-line treatment with capecitabine monotherapy (C), capecitabine and bevacizumab (CB), or capecitabine, bevacizumab, and mitomycin (CBM), in a 1 : 1 : 1 ratio. The primary end point of this trial was PFS with overall survival (OS) reported as a secondary end point. Only patients who provided prior written consent for their clinical data and tumour material to be used in subsequent translational studies are included in the current study. Ethics approval for translational studies was obtained centrally from the Human Research Ethics Committee, Austin Health.
Gene expression profiling on tumour samples
Archival formalin-fixed, paraffin-embedded (FFPE) samples of primary tumours from patients on the MAX study were retrieved. The tumours analysed were those obtained at primary resection and before any treatment. H&E stained sections were submitted for pathology review and macro-dissected to obtain tumour-rich tissue for RNA profiling. RNA purified from whole tumour sections was amplified to complementary DNA (cDNA) for microarray hybridization. Samples were processed in randomized batches for RNA extraction and amplification to minimize technical batch effects. Quality control measures were applied to determine the suitability of RNA and cDNA for use at each step of processing. Gene expression profiling was carried out using Almac Xcel microarray (Almac, Craigavon, UK), which interrogates over 97 000 transcripts, using Affymetrix GeneChip technology optimized for use with FFPE tissues [5] .
CMS classification
Transcriptome data obtained by the above methods were used to classify tumours into CMS groups using the previously reported consensus method [4] . CMS classification was carried out independently at the Swiss Institute of Bioinformatics (SIB, Lausanne, Switzerland), with the bioinformaticians blinded from all clinical data. In the published CMS classification method, up to 13% of CRC tumours remain unclassified using the 'predicted-CMS' algorithm. These unclassified samples are thought to represent mixed subtypes, or samples that fall outside the cutoffs of the classification algorithm. Unclassified samples could be avoided by using the 'nearest-CMS' algorithm (also provided by the CRC Subtyping Consortium), which classified all samples to the nearest CMS class. In order to maximize power for the outcomes analyses, we have presented our findings and conclusions using the 'nearest-CMS' classification. However, sensitivity analyses using the 'predicted-CMS' classification are presented as supplementary data, available at Annals of Oncology online.
Primary tumour location and other molecular features
Tumours originating in the splenic flexure, descending colon, sigmoid colon, or rectum were classified as left-sided; and tumours originating in the appendix, caecum, ascending colon, hepatic flexure, or transverse colon were classified as right-sided. MSI was determined by analysis of genomic DNA purified from FFPE tumour sections, using the MSI Analysis System (Promega) [6] . CIMP status was evaluated by analysis of genomic DNA purified from FFPE tumour sections, using the methylight assay for five CIMP marker genes (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) [7] . BRAF V600E and extended RAS (KRAS exons 2, 3, 4 and NRAS exons 2, 3, 4) mutation testing in the MAX cohort have been reported previously [8, 9] .
Statistical analyses
Survival outcomes of interest were PFS and OS, with similar methods used for analyses on both outcomes. To assess the prognostic ability of CMS, KaplanÀMeier plots were generated and differences between survival curves investigated using the log-rank test. The univariate association of CMS with survival was investigated using a proportional hazards Cox model. To investigate the predictive ability of CMS, a treatment-by-CMS interaction term was fitted alongside the main effects of CMS and treatment. As survival outcomes of the CB and CBM arms were similar in the MAX trial, they were combined as a single treatment arm (CB þCBM) and compared with C for the treatment-by-CMS analysis. Multivariate analyses were carried out adjusting the effect of CMS for prognostic factors previously found in the MAX cohort [3, 8, 9] . This included BRAF mutation status, but not KRAS or all-RAS mutations as they were not previously found to be prognostic in MAX. Due to the significant interaction of CMS with treatment (CB þ CBM versus C) that was found for PFS, prognostic impact of CMS for PFS outcome was analysed only in the C monotherapy arm. To investigate the relationship of CMS groups with other molecular features of interest (RAS mutation, BRAF mutation, MSI, and CIMP) a Fisher's exact test was used.
All reported P values were two sided.
Results

Patient characteristics and features of CMS groups
Archival primary tumour blocks from 262 patients were available for the CMS sub-study. Of these, some were excluded due to insufficient tumour tissue (n ¼ 7), inadequate RNA (n ¼ 4), and failing to meet microarray quality metrics (n ¼ 14) (supplementary Figure S1 , available at Annals of Oncology online). Hence samples from 237 patients (50% of trial population) were included in the CMS sub-study. The distribution of CMS groups was 18% for CMS1, 47% for CMS2, 12% for CMS3 and 23% for CMS4, using nearest-CMS labels. Using predicted-CMS labels, 16% (n ¼ 38) samples were unclassified. Baseline characteristics of patients in the CMS substudy were comparable to that in the primary study (Table 1) , and the magnitude of PFS benefit between treatment arms reported in the primary study (median PFS 5.7 versus 8.4 months, HR 0.61, 95% CI 0.50-0.74, P < 0.001) was similarly observed in the sub-study population (median PFS 6.0 versus 8.6 months, HR 0.68, 95% CI 0.50-0.90, P ¼ 0.009) (supplementary Figure S2 , available at Annals of Oncology online).
In the CMS sub-study cohort, 72 (30%) patients had rightsided primary tumours, 159 (67%) left-sided and 8 (3%) were unknown or indeterminate ( Table 1 Table 1) .
Correlation of CMS groups with molecular features of interest: extended RAS mutations, BRAF V600E mutations, MSI and CIMP status, are presented (supplementary Table S1 , available at Annals of Oncology online). RAS mutations were detected in 88 (37%) patients and there was no significant difference in the proportion of mutant versus wild-type tumours across CMS groups. The incidence of BRAF V600E mutations was highest in CMS1 (34%) compared with CMS2 and 4 (each <2%). The overall Original
Finally, the frequency of CIMP-high tumours was highest in CMS1 (39%) compared with CMS2 (3%) and CMS4 (6%).
Prognostic value of CMS
There was a significant difference in OS between CMS groups for all patients, regardless of first-line treatment in the MAX study (Log-rank P ¼ 0.008, Figure 1A and Table 2 ), but no difference was observed for PFS (assessed in C arm only, P ¼ 0.09, Table S2 , available at Annals of Oncology online). In a multivariate model adjusting for prognostic variables previously found in MAX [3, 8] and randomized treatment, CMS was an independent prognostic factor for OS (P ¼ 0.009, Table 2 ).
Predictive value of CMS for bevacizumab benefit
There was a significant interaction between CMS group and treatment in PFS (P-interaction ¼ 0.03) but not for OS (P-interaction ¼ 0.07, Table 2 ). Significant improvements in PFS for the addition of bevacizumab to chemotherapy (CB þ CBM versus C) were seen in CMS2 (HR 0.50; 95% CI 0.33-0.76) and CMS3 (HR 0.31; 95% CI 0.13À0.75), but not for CMS1 (HR 0.83; 95% CI 0.43À1.62) or CMS4 (HR 1.24; 95% CI 0.68À2.25) ( Figure 1B and C). Sensitivity analysis using the predicted-CMS labels supported these findings (supplementary Table S2 , available at Annals of Oncology online). The interaction between CMS and treatment remained significant (P-interaction ¼ 0.04, Table 2 ) after adjusting for prognostic variables previously found to influence PFS in the MAX study [3] .
Prognostic impact of primary tumour location
Due to clinical interest, we also assessed the prognostic impact of primary tumour location (left versus right) in this study. We previously reported that patients in the MAX trial with left-sided primary tumours had significantly improved OS compared with those with right-sided tumours (HR 0.67, 95% CI 0.53-0.85, P ¼ 0.001) [10] . Although the same trend of association between primary tumour side and OS was observed in the current CMS sub-study population, the difference was not statistically significant (HR 0.78, 95% CI 0.56-1.09, P ¼ 0.15, supplementary Figure S3 , available at Annals of Oncology online). For this reason, primary tumour side was not included in the multivariable model for prognostic associations in Table 2 .
Discussion
The CMS classification was developed using data from predominantly early-stage CRC and was shown to be prognostic in these cohorts [4] . Few studies have assessed the impact of CMS on outcomes in metastatic disease, and interactions of CMS with treatment, including biologic agents, are not yet established. In this hypothesis-generating study, we found that CMS classification is able to stratify outcomes in metastatic CRC, including possible prediction of outcomes with bevacizumab treatment in the first-line setting. Supporting the correct application of CMS classifier to our study cohort, several clinical and molecular correlates of CMS described in the CMS discovery cohorts [4] , including the enrichment of right-sided primary tumours in CMS1, enrichment of left-sided primary tumours in CMS2, and the associations of BRAF mutation, CIMP-high and MSI in CMS1, were similarly observed in the current study. Conversely, we failed to identify a statistically significant enrichment of KRAS mutation in CMS3 seen in previous cohorts [4] , although numerically the incidence of KRAS and extended RAS mutations were highest in CMS3 (39% and 46%, respectively). The small numbers of CMS3 tumours in our study (N ¼ 28) may have contributed to this effect.
Besides the current study, CMS analyses in two other metastatic CRC trial cohorts, FIRE-3 and CALGB 80405, have been recently reported, though not yet published [11, 12] . Both of these were randomized trials involving KRAS wild-type patients treated with cetuximab or bevacizumab in combination with first-line chemotherapy for metastatic CRC. The CMS associations in these studies are not directly comparable to the current study as FIRE-3 and 80 405 selected for KRAS wild-type patients while MAX did not have mutation selection criteria, and furthermore, treatments including biologicals and chemotherapy backbone differed. Nevertheless despite the differences across these three studies, it is interesting to note that the prognostic patterns of CMS are highly consistent, with CMS2 having the best prognosis and CMS1 the worst.
Notably, the prognostic effects of CMS in metastatic disease are distinct from those seen in early-stage disease, where CMS1 has the best relapse-free survival, and CMS4 the worst [4] . However, when survival-after-relapse was assessed in these earlystage cohorts [4] , the prognostic effects of CMS are consistent with those seen in the metastatic cohorts, including the current study. Altogether these studies indicate that the prognostic effects of CMS are stage-dependent.
An intriguing finding in this exploratory study is the statistically significant interaction between CMS and treatment outcome in PFS. Specifically, patients with CMS2 and possibly CMS3 (limited by small numbers) tumours preferentially benefitted from the addition of bevacizumab to capecitabine-based chemotherapy compared with the other CMS groups. Interestingly, there was a trend for reduced PFS in CMS4 patients treated with bevacizumab; although this was not a statistically significant result and hence must be regarded as inconclusive.
Although the specific mechanisms underlying the interaction of CMS groups with bevacizumab treatment is not clear, it is notable that CMS2 and CMS3, which derived more benefit from bevacizumab, share features of highly proliferative epithelial cancers, distinct from CMS1 and CMS4 which are associated with high immune and stromal infiltration, respectively [13] . Furthermore, tumours are known to utilize different mechanisms of vascularization including classic angiogenesis, and nonangiogenic mechanisms such as vessel co-option and vascular mimicry [14, 15] . Notably vessel co-option, where cancer cells are able to utilize surrounding host vessels, is proposed as a mode of tumour resistance to bevacizumab, including in CRC liver metastases [16, 17] . While the mechanisms of tumour vascularization in the different CMS groups are currently unknown, an intriguing possibility that is worthy of further investigation is that tumours with high stromal infiltration (CMS4) preferentially utilize vessel co-option, while epithelial subtypes (CMS2/3) rely on classic angiogenesis, making them more likely to respond to bevacizumab.
The results of this study have some limitations. Our predictive findings are hypothesis-generating, recognizing the small numbers and lack of validation in another cohort. Furthermore, as Original article Annals of Oncology outlined above, the specific biological basis underlying the interaction of CMS groups with bevacizumab treatment remains to be determined.
Other limitations relate to application of the CMS classifier as it stands. While using molecular classification of primary tumour samples to predict outcomes in metastatic disease represent a practical approach that we and others have taken, the consistency of CMS class in the temporal evolution of CRC remains unclear. Further studies are required to assess concordance of CMS status in sequential primary and metastatic lesions, and their corresponding impact on survival. Further refinement of the CMS classifier to address unclassified samples or further sensitivity analyses to assess the association of nearest-CMS and predicted-CMS labels to outcomes in additional cohorts are required before CMS can progress as a useful biomarker in the field.
In conclusion, this hypothesis-generating study found that CMS was highly prognostic in metastatic CRC, with CMS2 associated with the best outcome and CMS1 the worst. Furthermore a significant interaction of CMS with bevacizumab treatment was found, where CMS2 and possibly CMS3 may preferentially benefit from the addition of bevacizumab to capecitabine-based chemotherapy in first-line treatment of metastatic CRC. These findings offer possible insights into the molecular profiles that may condition response to antiangiogenesis treatment in metastatic CRC and warrant further validation in additional cohorts. Finally, this study, amongst others, demonstrates the feasibility of applying the CMS classifier to clinical samples, and the potential for comprehensive molecular stratification of CRC to inform prognosis and treatment selection.
